|
Gene: COQ7 |
Gene summary for COQ7 |
Gene summary. |
Gene information | Species | Human | Gene symbol | COQ7 | Gene ID | 10229 |
Gene name | coenzyme Q7, hydroxylase | |
Gene Alias | CAT5 | |
Cytomap | 16p12.3 | |
Gene Type | protein-coding | GO ID | GO:0006743 | UniProtAcc | Q99807 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10229 | COQ7 | LZE4T | Human | Esophagus | ESCC | 4.43e-07 | 2.12e-01 | 0.0811 |
10229 | COQ7 | LZE7T | Human | Esophagus | ESCC | 2.56e-05 | 2.52e-01 | 0.0667 |
10229 | COQ7 | LZE20T | Human | Esophagus | ESCC | 8.28e-08 | 3.12e-01 | 0.0662 |
10229 | COQ7 | LZE24T | Human | Esophagus | ESCC | 2.28e-11 | 2.10e-01 | 0.0596 |
10229 | COQ7 | LZE21T | Human | Esophagus | ESCC | 1.35e-05 | 2.05e-01 | 0.0655 |
10229 | COQ7 | P1T-E | Human | Esophagus | ESCC | 1.04e-16 | 5.93e-01 | 0.0875 |
10229 | COQ7 | P2T-E | Human | Esophagus | ESCC | 2.71e-38 | 7.18e-01 | 0.1177 |
10229 | COQ7 | P4T-E | Human | Esophagus | ESCC | 2.69e-17 | 3.49e-01 | 0.1323 |
10229 | COQ7 | P5T-E | Human | Esophagus | ESCC | 5.86e-12 | 2.24e-01 | 0.1327 |
10229 | COQ7 | P8T-E | Human | Esophagus | ESCC | 6.04e-19 | 3.05e-01 | 0.0889 |
10229 | COQ7 | P9T-E | Human | Esophagus | ESCC | 2.67e-12 | 1.98e-01 | 0.1131 |
10229 | COQ7 | P10T-E | Human | Esophagus | ESCC | 3.55e-13 | 1.72e-01 | 0.116 |
10229 | COQ7 | P11T-E | Human | Esophagus | ESCC | 1.22e-03 | 2.59e-01 | 0.1426 |
10229 | COQ7 | P12T-E | Human | Esophagus | ESCC | 2.03e-29 | 5.25e-01 | 0.1122 |
10229 | COQ7 | P15T-E | Human | Esophagus | ESCC | 2.22e-15 | 3.22e-01 | 0.1149 |
10229 | COQ7 | P16T-E | Human | Esophagus | ESCC | 7.90e-34 | 5.16e-01 | 0.1153 |
10229 | COQ7 | P17T-E | Human | Esophagus | ESCC | 4.05e-03 | 2.20e-01 | 0.1278 |
10229 | COQ7 | P20T-E | Human | Esophagus | ESCC | 7.50e-24 | 5.95e-01 | 0.1124 |
10229 | COQ7 | P21T-E | Human | Esophagus | ESCC | 9.64e-26 | 2.68e-01 | 0.1617 |
10229 | COQ7 | P22T-E | Human | Esophagus | ESCC | 3.96e-21 | 4.29e-01 | 0.1236 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
GO:190166112 | Esophagus | ESCC | quinone metabolic process | 34/8552 | 40/18723 | 3.00e-07 | 4.27e-06 | 34 |
GO:200037718 | Esophagus | ESCC | regulation of reactive oxygen species metabolic process | 100/8552 | 157/18723 | 3.87e-06 | 4.17e-05 | 100 |
GO:00067432 | Esophagus | ESCC | ubiquinone metabolic process | 17/8552 | 19/18723 | 9.02e-05 | 6.50e-04 | 17 |
GO:007259318 | Esophagus | ESCC | reactive oxygen species metabolic process | 137/8552 | 239/18723 | 1.82e-04 | 1.16e-03 | 137 |
GO:00067442 | Esophagus | ESCC | ubiquinone biosynthetic process | 15/8552 | 17/18723 | 3.48e-04 | 2.03e-03 | 15 |
GO:19016632 | Esophagus | ESCC | quinone biosynthetic process | 15/8552 | 17/18723 | 3.48e-04 | 2.03e-03 | 15 |
GO:00421805 | Esophagus | ESCC | cellular ketone metabolic process | 120/8552 | 211/18723 | 6.70e-04 | 3.55e-03 | 120 |
GO:000756818 | Oral cavity | OSCC | aging | 194/7305 | 339/18723 | 6.18e-12 | 2.33e-10 | 194 |
GO:19016613 | Oral cavity | OSCC | quinone metabolic process | 32/7305 | 40/18723 | 1.40e-07 | 2.34e-06 | 32 |
GO:200037716 | Oral cavity | OSCC | regulation of reactive oxygen species metabolic process | 92/7305 | 157/18723 | 4.96e-07 | 7.27e-06 | 92 |
GO:00421804 | Oral cavity | OSCC | cellular ketone metabolic process | 111/7305 | 211/18723 | 3.94e-05 | 3.45e-04 | 111 |
GO:0006743 | Oral cavity | OSCC | ubiquinone metabolic process | 16/7305 | 19/18723 | 7.05e-05 | 5.60e-04 | 16 |
GO:007259316 | Oral cavity | OSCC | reactive oxygen species metabolic process | 122/7305 | 239/18723 | 9.73e-05 | 7.34e-04 | 122 |
GO:0006744 | Oral cavity | OSCC | ubiquinone biosynthetic process | 14/7305 | 17/18723 | 3.31e-04 | 2.04e-03 | 14 |
GO:1901663 | Oral cavity | OSCC | quinone biosynthetic process | 14/7305 | 17/18723 | 3.31e-04 | 2.04e-03 | 14 |
GO:0042181 | Oral cavity | OSCC | ketone biosynthetic process | 26/7305 | 43/18723 | 3.55e-03 | 1.49e-02 | 26 |
GO:000756819 | Oral cavity | LP | aging | 125/4623 | 339/18723 | 3.29e-07 | 9.62e-06 | 125 |
GO:200037717 | Oral cavity | LP | regulation of reactive oxygen species metabolic process | 67/4623 | 157/18723 | 5.54e-07 | 1.51e-05 | 67 |
GO:190166111 | Oral cavity | LP | quinone metabolic process | 24/4623 | 40/18723 | 2.17e-06 | 4.85e-05 | 24 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012405 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
hsa0124012 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
hsa012404 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa00130 | Oral cavity | OSCC | Ubiquinone and other terpenoid-quinone biosynthesis | 9/3704 | 11/8465 | 1.19e-02 | 2.62e-02 | 1.33e-02 | 9 |
hsa0124011 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa001301 | Oral cavity | OSCC | Ubiquinone and other terpenoid-quinone biosynthesis | 9/3704 | 11/8465 | 1.19e-02 | 2.62e-02 | 1.33e-02 | 9 |
hsa001302 | Oral cavity | LP | Ubiquinone and other terpenoid-quinone biosynthesis | 8/2418 | 11/8465 | 3.03e-03 | 1.29e-02 | 8.35e-03 | 8 |
hsa0124021 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
hsa001303 | Oral cavity | LP | Ubiquinone and other terpenoid-quinone biosynthesis | 8/2418 | 11/8465 | 3.03e-03 | 1.29e-02 | 8.35e-03 | 8 |
hsa0124031 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
COQ7 | SNV | Missense_Mutation | rs763027324 | c.371N>T | p.Ala124Val | p.A124V | Q99807 | protein_coding | tolerated(0.1) | benign(0.408) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
COQ7 | SNV | Missense_Mutation | novel | c.578N>A | p.Ala193Asp | p.A193D | Q99807 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
COQ7 | SNV | Missense_Mutation | novel | c.296N>G | p.Glu99Gly | p.E99G | Q99807 | protein_coding | deleterious(0.01) | possibly_damaging(0.593) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
COQ7 | SNV | Missense_Mutation | rs746195092 | c.103C>T | p.Arg35Cys | p.R35C | Q99807 | protein_coding | tolerated(0.19) | benign(0) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
COQ7 | SNV | Missense_Mutation | novel | c.516N>T | p.Lys172Asn | p.K172N | Q99807 | protein_coding | deleterious(0.01) | possibly_damaging(0.694) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
COQ7 | SNV | Missense_Mutation | novel | c.142N>A | p.Ala48Thr | p.A48T | Q99807 | protein_coding | tolerated(0.44) | benign(0.001) | TCGA-LG-A9QD-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | sorafenib | SD |
COQ7 | SNV | Missense_Mutation | novel | c.71C>T | p.Ser24Leu | p.S24L | Q99807 | protein_coding | tolerated(0.07) | benign(0.051) | TCGA-73-A9RS-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD |
COQ7 | SNV | Missense_Mutation | novel | c.368N>T | p.Gly123Val | p.G123V | Q99807 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-78-8662-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
COQ7 | SNV | Missense_Mutation | c.232A>T | p.Ser78Cys | p.S78C | Q99807 | protein_coding | deleterious(0.01) | probably_damaging(0.957) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
COQ7 | SNV | Missense_Mutation | c.632N>C | p.Ile211Thr | p.I211T | Q99807 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-HI-7168-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Hormone Therapy | lupron | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |